NasdaqGS:ERASBiotechs
Does Erasca’s US$225 Million Equity Raise and ERAS-0015 Data Change The Bull Case For ERAS?
In January 2026, Erasca, Inc. completed a follow-on equity offering of 22,500,000 common shares at US$10.00 each, raising US$225,000,000 with a US$0.60 per-share discount.
This capital raise, alongside encouraging clinical progress for ERAS-0015 showing partial responses without dose-limiting toxicities, materially reinforces Erasca’s ability to fund its development pipeline.
We’ll now explore how the strengthened balance sheet from this offering influences Erasca’s investment narrative and...